Podcasts about Mash

100 years ago this year, celebrated director Robert Altman was born. To celebrate his legacy and influence on film, the Criterion Channel has launched a new September series, Directed by Robert Altman. The series includes films like "The Player," "The Long Goodbye," and "MASH." Sean Fennessey, co-host of "The Big Picture" and curator of the Criterion series, joins to discuss. Plus, callers share their favorite Robert Altman movies.

MASH debuted on this day and Nick Cannon talks about why he had 12 kids. 

Jeff & Ryan welcome Greg Izay to MASH Matters! Greg's mother, Connie, was the on-set medical technical advisor on M*A*S*H. We remember Connie through Greg's stories about her beginnings in the industry, how she helped actors look like real surgeons, her long career behind the scenes, and her brief moments ON screen. Plus - the M*A*S*H/Smokey & the Bandit crossover you've been waiting for!   Support the podcast on Patreon and buy merch at the MASH Matters store   For show notes, episodes, recipes, bios, and more visit our website.  

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for September 5-September 14, 2025: 1. FDA Removes Sparsentan (Filspari) Advisory Committee Meeting for FSGS sNDA The FDA determined no advisory committee is needed for sparsentan's sNDA in FSGS, which remains under review with a January 2026 decision date. 2. Intercept Voluntarily Withdraws Obeticholic Acid (Ocaliva) for PBC From US Market Intercept will withdraw obeticholic acid from the US PBC market after an FDA request and related clinical trial holds. 3. FDA Accepts FibroScan Letter of Intent for Surrogate Endpoint in MASH Trials The FDA accepted a proposal to qualify FibroScan liver stiffness measurement as a surrogate endpoint for MASH trials, supported by multiple industry partners. 4. FDA Clears IND Application for EGEN-2784, a Genetically Engineered Pig Kidney, for ESKD eGenesis received FDA clearance to begin clinical testing of a genetically engineered porcine kidney transplant in patients with ESKD. 5. First in Class Cat, Birch Allergen Blockers Succeed in Phase 3 Trials Regeneron reported phase 3 success for novel allergen-blocking antibodies targeting cat and birch allergies, with confirmatory trials planned.

M*A*S*H was a Robert Altman directed 1970 Oscar nominee for Best Picture. What war was depicted in the move M*A*S*H? Play. Share. Listen with actor Fred Grandy. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The FDA has endorsed vibration-controlled transient elastography as a surrogate endpoint for MASH trials, marking the first non-invasive alternative to liver biopsy. A Japanese cohort study linked breakfast skipping and late dinners to higher fracture risk, with combined habits raising risk by nearly 25%. Finally, a global meta-analysis suggests shingles vaccination reduces major cardiovascular events by ~16–18%, though most evidence is observational.

Welcome to Week In Geek Wednesday for our quick-hits segment of entertainment and interesting bits of internet debris for you... the people! In this episode, we talk about fantasy football teams, the return of AJ Lee to WWE, college move-in day, and Katee Sackhoff's troubles after Bo Katan!   FULL VIDEO EPISODES! That's right folks, you can see our bright smiling idiotic faces in full color on our YouTube channel. Full episodes available as well as clips.   LINKS OF INTEREST: - Unfortunate story around Katie Sackhoff's post-Mando experience - Here's the YouTube clip from The Sackhoff Show   ...AND ANOTHER THING: The Man They Call Tim suggests watching “What Do You Want To Talk About With Cody Rhodes" with guest Bruce Pritchard on YouTube Uncle Todd suggests watching "M*A*S*H" streaming on Disney+   FOLLOW US ON THE SOCIAL MEDIAS: Facebook - http://facebook.com/freerangeidiocy Instagram - http://instagram.com/freerangeidiocy YouTube - http://youtube.com/@freerangeidiocy

In this episode of the Xtalks Life Science Podcast, Editor-in-Chief Vera Kovacevic speaks with Rohan Palekar, CEO of 89bio, about one of the fastest-growing public health challenges: metabolic dysfunction-associated steatohepatitis (MASH), also known as fatty liver disease. MASH is projected to affect more than 27 million Americans by 2030, yet it remains a largely “silent” epidemic. Palekar discusses what sets MASH apart from other liver diseases, the urgent need for therapies that can rapidly reverse fibrosis in advanced patients and the unique challenges drug developers face in addressing this condition. The conversation explores the drivers behind the sharp rise in MASH prevalence and what may define the future therapeutic landscape. Palekar also reflects on his leadership journey at 89bio and shares what's next for the company as it advances new therapies for MASH and beyond. Tune in to learn how 89bio is working to transform care for patients living with MASH and why this disease represents one of the most important — yet underrecognized — health challenges of the decade. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Molecular biologist and Nobel Prize winner David Baltimore made foundational contributions to the biopharma industry and was the essential figure behind such research institutions as the Whitehead Institute for Biomedical Research and the Broad Institute. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the legacy of Baltimore, who passed away this past weekend at 87.The analysts also discuss Atlas Venture's new $400 million opportunity fund, the clinical development pipelines for metabolic-associated steatohepatitis (MASH) and chronic urticaria, and late-stage atopic dermatitis data from Sanofi. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656942#biotech #biopharma #DavidBaltimore #ReverseTranscriptase #MASH #Rezdiffra #GLP1 #ChronicUrticaria #Dupixent00:01 - Sponsor Message: IQVIA Biotech03:19 - Remembering David Baltimore06:20 - Atlas' New Opportunity Fund09:16 - The Growing MASH Pipeline15:57 - Sanofi's Atopic Dermatitis Data18:51 - Exploring Chronic Urticaria TreatmentsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Send us a textLast month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, initially developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy conversation, but one key point is that screening a mass population for HCC or cirrhosis has an entirely different set of issues and criteria compared to the screening usually discussed on this podcast, which involves identifying a population at increased risk for MASLD or MASH and screening them. Also, healthcare is far more expensive than it was in 1960 with a plethora of high-cost ways to diagnose, treat and manage patients.As a result, the authors started with the 10 Wilson and Jungner criteria and added eight more. During this conversation, Stine emphasizes the need for a comprehensive clinical trial on this issue, and all panelists agree that LiverAIM is likely to serve as the study.

Send us a textThis discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Louise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. The discussion also extends to the role of NITs in diagnosis and patient management, and how providers need to shift the paradigm away from describing a patient by fibrosis stage and instead focus on the amount of fat in the liver and its overall suppleness.

Kayla texted in to ask if we'd ever had carrots and honey, so we made it our Mash it Up Monday combo!

05.09.25 Pt 2 - Gareth is joined by Mash and Ben for a hilarious deep dive into some questionable bathroom habits — including whether it's humanly possible to sneeze and use the toilet at the same time. The trio then debates double standards between men and women, and wrap things up by asking: when someone says “let me finish,” does it actually mean they're talking nonsense? The Real Network

Send us a text00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discuss their recent publication in The Lancet, titled "Screening for Advanced Liver Disease." 00:04:45 - Major Issues of the First Six Months: Integrated Patient ManagementLouise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. 00:21:02 - Newsmakers: Aleksander Krag and Stine Johansen discuss Screening for Advanced Liver DiseaseLast month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, originally developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy conversation, but the key point is that screening a mass population for HCC or cirrhosis has an entirely different set of issues and criteria compared to the screening usually discussed on this podcast, which involves identifying a population at increased risk for MASLD or MASH and screening them. 00:54:42 - Major Issues of the First Six Months: Changes in US Health Policy and Potential for Dynamism in the In-Office Scanning Market Roger drives this conversation, focusing on two very different, yet very important issues: the first is the increasing dynamism of the in-office scanning market, with leader Echosens developing new products and services, while companies like e-Scopics, Sonic Incytes, and Mindray (Hepatus) are introducing new devices with competing profiles. Roger discusses the idea that some scanners keep all data resident in the machine, while others send it immediately to the cloud. Louise suggests that we should welcome any reliable scanning device to the market. Separately, he lists some concerns about how the Trump Administration's focus on cutting services to the poor, coupled with Robert F. Kennedy Jr.'s distrust of pharmaceuticals and mainstream health research, might limit the number of Americans with access to healthcare and the kinds of care they can access. At the end of this conversation, Roger asks Jörn and Louise what they consider major issues for the next six months.01:11:40 - Business Report and Wrap-Up

Send us a textInteresting things about the distillery:Ryan is from the military and Holly worked with airlinesRyan is also a glassblowerNames of the bottles are based on glassblowing itemsDidymium is a purple filtering glass that glassblowers wear to protect their eyes, filtering out all the other bottles on the shelfThe Gaffer collection is their limited release, and a Gaffer is the head glassblowerThe First batch just released includes 20% Amaranth which is similar to wheatVERY Small production.  You can join the founders club on their website to help them grow and purchase a distilleryOur Bottle: Didymium Bourbon Batch:Batch 1: Release Nov. 2024. Mash bill 80% purple corn, 15% rye, 5% malt. Barrel Char 3Batch 2: Release Dec. 2024. Mash bill 80% purple corn, 5% rye, 5% malt. Barrel Char 3Batch 3: Release Mar. 2025. Mash bill 75% purple corn, 15% rye, 10% malt. Barrel Char 3Batch 4: Release Jun. 2025. Mash bill 75% purple corn, 15% rye, 10% malt. Barrel Char 4Pipe Pairings: Dunhill flakeCocktails:Support the showWebsite:www.whiskeychaserspod.comFacebook:https://www.facebook.com/whiskeychaserspodcastInsta:https://www.instagram.com/whiskeychaserspodcast/TikTok:https://www.tiktok.com/@whiskeychaserspodcastThanks For Listening! Tell a Friend!

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologies and an expanded APP population will play in MASLD and MASH management in the US, and concludes by exploring how care might look different 12 months from now, and then in subsequent years. As panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients, many comments touch on themes discussed earlier in this episode. A couple are unique. Zobair and Scott discuss the increased role that artificial intelligence and big data analytics will play in identifying high-risk patients and improving clinical pathways. Additionally, Zobair notes that we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scott anticipates a "paradigm shift" in which endocrinologists view MASH similarly to how they view retinopathy, neuropathy and retinopathy. Naim suggests that one year will not look tremendously different from today, but that five years from now will be an entirely different picture, which he describes in some detail. 

ATTENTION! This is an audio recording of the latest MASH Matters video livestream. We strongly encourage you to WATCH this episode on YouTube to see Jeff & Ryan's ugly mugs (faces), pretty mugs (cups), old TV clips, and a surprise appearance by Walter Eugene Patrick! This livestream aired live on August 31, 2025. CLICK HERE TO WATCH THE LIVESTREAM REPLAY ON YOUTUBE

What kinds of things do neutron stars do? They can smash into each other, producing bright flashes of radiation and strong ripples in spacetime that can be detected across the universe! Or, a neutron star can just be sitting there, and its magnetic field might suddenly shift and produce a dramatic burst of radio waves! But mainly, neutron stars are super-dense and super-complicated, giving us a probe of fundamental physics in its most extreme limits. Dr. Wen-Fai Fong tells us all about how we can learn more!

Join us as we recap this classic 1970's sitcom. There's tons of fun trivia, discussion of the biggest pop culture news that dropped on the day we recorded this podcast and a discussion of Cheers without Sam and MASH with Hawkeye. We also mention: The Love Boat, Fantasy Island, Lucille Ball, Frasier and...Seinfeld!

THE BEST HUNGER GAMES MOVIE?! The Hunger Games: Catching Fire Full Movie Reaction Watch Along:   / thereelrejects   Get your New Customer offer + 3-month Unlimited wireless plan for just 15 bucks a month at https://www.mintmobile.com/REJECTS Support The Channel By Getting Some REEL REJECTS Aparrel! https://www.rejectnationshop.com/ With The Hunger Games: Sunrise on the Reaping on the horizon, Aaron & Andrew continue their journey giving their The Hunger Games: Catching Fire Reaction, Recap, Analysis, & Spoiler Review! The Hunger Games: Catching Fire (2013), directed by Francis Lawrence, continues the epic dystopian saga based on Suzanne Collins' bestselling novels. Jennifer Lawrence (Silver Linings Playbook, X-Men: First Class) returns as Katniss Everdeen, who finds herself once again thrust into the deadly Hunger Games arena after her defiance in the previous installment inspires rebellion across Panem. Josh Hutcherson (Bridge to Terabithia, The Kids Are All Right) stars as Peeta Mellark, her fellow victor and partner in survival, while Liam Hemsworth (The Last Song, Independence Day: Resurgence) plays Gale Hawthorne, torn between loyalty and revolution. Donald Sutherland (The Italian Job, MAS*H) returns as the chilling President Snow, joined by Philip Seymour Hoffman (Capote, The Master) as the sly new Gamemaker, Plutarch Heavensbee. Supporting performances include Woody Harrelson (True Detective, Zombieland) as Haymitch, Elizabeth Banks (Pitch Perfect, The Lego Movie) as Effie Trinket, and Stanley Tucci (The Devil Wears Prada, Spotlight) as the flamboyant Caesar Flickerman. From Katniss and Peeta's unforgettable Victory Tour to the shocking Quarter Quell reveal, the film builds to one of the franchise's most iconic cliffhangers. With stunning visuals, political intrigue, and the unforgettable “girl on fire” moments, Catching Fire set the stage for the Mockingjay films while cementing Katniss Everdeen as one of cinema's most enduring heroes. Join Aaron Alexander & Andrew Gordon as they react, review, and break down the most emotional, action-packed, and game-changing moments of this blockbuster sequel. Follow Aaron On Instagram: https://www.instagram.com/therealaaronalexander/?hl=en Follow Andrew Gordon on Socials:  YouTube: https://www.youtube.com/@MovieSource Instagram:  https://www.instagram.com/agor711/?hl=en Twitter:  https://twitter.com/Agor711 Intense Suspense by Audionautix is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... Support The Channel By Getting Some REEL REJECTS Apparel! https://www.rejectnationshop.com/ Follow Us On Socials:  Instagram: https://www.instagram.com/reelrejects/  Tik-Tok: https://www.tiktok.com/@reelrejects?lang=en Twitter: https://x.com/reelrejects Facebook: https://www.facebook.com/TheReelRejects/ Music Used In Ad:  Hat the Jazz by Twin Musicom is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Happy Alley by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... POWERED BY @GFUEL Visit https://gfuel.ly/3wD5Ygo and use code REJECTNATION for 20% off select tubs!! Head Editor: https://www.instagram.com/praperhq/?hl=en Co-Editor: Greg Alba Co-Editor: John Humphrey Music In Video: Airport Lounge - Disco Ultralounge by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Ask Us A QUESTION On CAMEO: https://www.cameo.com/thereelrejects Follow TheReelRejects On FACEBOOK, TWITTER, & INSTAGRAM:  FB:  https://www.facebook.com/TheReelRejects/ INSTAGRAM:  https://www.instagram.com/reelrejects/ TWITTER:  https://twitter.com/thereelrejects Follow GREG ON INSTAGRAM & TWITTER: INSTAGRAM:  https://www.instagram.com/thegregalba/ TWITTER:  https://twitter.com/thegregalba Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss  FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices.This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education. Another important benefit may come in terms of coverage. Scott points out that most patients living with obesity but not diabetes are unlikely to have their semaglutide prescriptions covered by commercial insurers. Those living with non-cirrhotic MASH are likely to have semaglutide covered. A separate but related point: Naim reports that ~30% of the MASH patients he sees are taking an incretin agonist at the time of initial visit.

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system must adapt to handle the growing number of MASH and MASLD patients who might seek treatment, given likely increases in publicity and education.The conversation starts with a focus on the implications of semaglutide approval for hepatologists. Naim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process.Zobair shifts to a larger point:  even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. The number of APPs necessary to handle this load and trained to do so does not currently exist in the US. Increased APP training must, and will, become an area for increased investment and focus.After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target, screen, diagnose and treat patients...given sufficient providers (mostly APPs) to treat them. 

Hollywood actor Alan Alda has devoted his life to science, by taking his acting and communication skills off the screen and into the laboratory. Alan grew up in a show business family and spent his childhood touring with a burlesque show run by his parents.He eventually made a name for himself in showbiz, becoming well-known and much-loved for his performances in M.A.S.H. and The West Wing, as well as his roles in many Hollywood films.Alan is also famous for his love of science.He wrote Dear Albert for the stage, based on the love letters of Albert Einstein, which reveal Einstein as a beautifully passionate man.Alan has used his acting for the good of science by teaching communication skills to scientists so they might make their work better known and better understood.Further informationThis interview was first broadcast in December 2016.2025 update:  Alan has been diagnosed with Parkinson's disease, but he says he's managing it well.  Alan is still working occasionally, most recently in the TV remake of his 1981 film ‘The Four Seasons'.You can read all about the Conversations origin story on the ABC News website.This episode of Conversations explores science, science communication, MASH, television, Hollywood, silver screen, acting, show biz families, family business, Vietnam, origin stories, memoir.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

Hollywood actor Alan Alda has devoted his life to science, by taking his acting and communication skills off the screen and into the laboratory. Alan grew up in a show business family and spent his childhood touring with a burlesque show run by his parents.He eventually made a name for himself in showbiz, becoming well-known and much-loved for his performances in M.A.S.H. and The West Wing, as well as his roles in many Hollywood films.Alan is also famous for his love of science.He wrote Dear Albert for the stage, based on the love letters of Albert Einstein, which reveal Einstein as a beautifully passionate man.Alan has used his acting for the good of science by teaching communication skills to scientists so they might make their work better known and better understood.Further informationThis interview was first broadcast in December 2016.2025 update:  Alan has been diagnosed with Parkinson's disease, but he says he's managing it well.  Alan is still working occasionally, most recently in the TV remake of his 1981 film ‘The Four Seasons'.You can read all about the Conversations origin story on the ABC News website.This episode of Conversations explores science, science communication, MASH, television, Hollywood, silver screen, acting, show biz families, family business, Vietnam, origin stories, memoir.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

Tommy Ruben joined me to discuss the closed knit cast of CPO Sharkey; growing up in Larchont, NY and his dad working for Sgt. Bilko; his dad Aaron, writing for Fred Allen, Milton Berle, Sid Caesar, The Andy Griffith Show and creating Gomer Pyle USMC; Don Rickles getting booed on Comic Relief; Sharkey's scripts scripts had ad-libs written in; being a class clown; guest starring on MASH; going to the Oakwood School; his dad''s film, The Comic; his father liked to build sitcoms around someone; creating CPO Sharkey; Polish jokes got the most letters; his first scene; episodes focusing on his character; the Johnny Carson incident and how has dad was mad; NBC wasn't all in on Don; Bob Newhart; his brother writing the punk rock episode; appearing in More American Graffiti with Cindy Williams; the difference in Drew Barrymore and James garner's acting methods; appearing and writing and episodes of The Stockard Channing Show; Rhonda Bates; being in his brothers movies; almost getting The Hardy Boys Show; and studying photography at the School of Visual Arts.

This week Megan and Evan took in director Rachel Abigail Holder's romantic drama LOVE, BROOKLYN (2:00), starring André Holland, Nicole Beharie, and DeWanda Wise. Short version: They liked it, with Megan revisiting it after seeing it at Sundance earlier this year. Next, Dave joins them for A LITTLE PRAYER (28:09), a quiet and understated Southern family drama from writer-director Angus MacLachlan, starring David Strathairn, Jane Lavy, and Celia Weston. Two of the three of us thought it was really well done, and one of us had hoped to like it more than they did. Such is life. Over on Patreon, we talk about Robert Altman's M*A*S*H, which turns 55 this year.

Send us a text00:00:00 - Surf's Up, Season 6, Episode 12This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having two drugs available will change MASH management in the US.00:08:45 - Part I: How Will The Semaglutide Approval Affect Patient Treatment and Pharmacotherapy?The group starts by describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education.00:25:30 - Part II: How the Structure of Medical Practice Is Likely To ChangeNaim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process. Zobair states that even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target patients, screen, diagnose and treat them. 00:44:17 - Part III: What Happens Next?In this final section, panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients. Many of the comments touch on themes discussed earlier in this episode, but a couple are unique. Zobair states we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scotts anticipates a "paradigm shift" in which providers come to view MASH similarly to how they view diabetic comorbidities. 

The FDA has granted accelerated approval to semaglutide (Wegovy) as the first drug for metabolic dysfunction–associated steatohepatitis (MASH), showing significant improvements in liver health and weight loss in the phase 3 ESSENCE trial. A systematic review of acetaminophen use in pregnancy found potential risks with long-term or frequent use but confirmed short-term, low-dose use remains appropriate when needed. Finally, an AI model integrating MRI, biomarkers, and clinical data improved prediction of knee osteoarthritis progression, enhancing physician accuracy and suggesting future support for earlier, personalized interventions.

On this episode of Life's Undertaking, Brad Jones tells Toronto Mike about the television shows he loves.

"If you love cats, you should be concerned about trying to help bring those numbers down so animals don't suffer because this is why we do this. We don't want animals suffering, having unwanted litters of cats and having to have them suffer." This episode is sponsored-in-part by Maddie's Fund and 6 Degrees of Cats. In this powerful episode, host Stacy LeBaron sits down with Cathy Bissell, founder of Bissell Pet Foundation, who has revolutionized animal welfare through innovative programs reaching over 6,000 shelters across 49 states. From her unexpected entry into animal welfare during Hurricane Katrina to creating the nation's largest funded adoption event, Cathy's journey demonstrates how strategic thinking and passionate commitment can create systemic change. Her foundation has impacted nearly one million pets since 2011, but it's her latest initiative that's truly disrupting the industry. Cathy shares the incredible success of her groundbreaking "Fix the Future" program, launched in 2023 to address the veterinary care access crisis. In just under 18 months, this free spay/neuter initiative has sterilized 138,000 animals across 27 states, with an astounding 86,963 of those being cats. Through a network of 385 high-volume, high-quality relief veterinarians, the program is tackling overpopulation at its source while keeping costs remarkably low at just $35 per surgery. Cathy discusses the challenges of scaling this model, the importance of treating every animal that comes through their doors, and why she believes this "disruptor program" is essential for breaking down cost barriers that prevent people from accessing veterinary care. Whether you're working in a small grassroots rescue or leading a major shelter, this episode provides invaluable insights into creating sustainable, scalable solutions that address root causes rather than just symptoms. Cathy's emphasis on collaboration, her honest discussion about learning from mistakes (including a powerful story about declawing), and her practical advice for getting started at any age will inspire listeners to think bigger about their impact and consider how they can contribute to solving the access to care crisis in their own communities. Press play now for: Cathy's unexpected journey from Hurricane Katrina volunteer to founding a major animal welfare foundation The evolution from disaster response to adoption events to addressing systemic access to care challenges Incredible statistics: 138,000 spay/neuter surgeries in 18 months with 86,963 cats across 27 states How the Fix the Future program operates with 385 relief veterinarians at just $35 per surgery The power of MASH-style clinics and why community cat advocates should consider creating their own Why Michigan serves as a prime example with 3,000 cats out of 4,000 total surgeries at their clinic The importance of spaying/neutering before adoption and addressing kittens under six months How veterinary school limitations (graduating with only 1-3 spay/neuter surgeries) impact private practice capacity Cathy's honest story about learning from the declawing controversy and how it changed her foundation's policies Practical advice for getting involved at any age and making a difference beyond just donating money The role of Empty the Shelters adoption events in supporting shelter operations nationwide Why every animal deserves vaccination and ear-tipping as part of comprehensive TNR programs Resources mentioned: Bissell Pet Foundation website (https://www.bissellpetfoundation.org/) Empty the Shelters adoption events (https://www.bissellpetfoundation.org/programs/empty-the-shelters/) Fix the Future spay/neuter initiative (https://www.bissellpetfoundation.org/programs/fix-the-future/) Mississippi State University College of Veterinary Medicine (https://www.vetmed.msstate.edu/) MSU shelter medicine program details (https://www.vetmed.msstate.edu/about/points-of-pride) United Spay Alliance website (https://www.unitedspayalliance.org/) United Spay Alliance wet lab training programs (https://www.unitedspayalliance.org/hqhvsn-wet-labs/) BISSELL Pet Foundation grant information (https://www.bissellpetfoundation.org/grant-information/) Operation Fix the Future clinics (https://www.bissellpetfoundation.org/operation-fix-the-future/) BISSELL Pet Foundation Facebook page (https://www.facebook.com/bissellpets/) Sponsor Links: Maddie's Fund (https://www.communitycatspodcast.com/maddies623) Six Degrees of Cats (https://podcasts.apple.com/us/podcast/6-degrees-of-cats/id1669849217) Follow & Review We'd love for you to follow us if you haven't yet. Click that purple '+' in the top right corner of your Apple Podcasts app. We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts(https://podcasts.apple.com/us/podcast/the-community-cats-podcast/id1125752101?mt=2). Select “Ratings and Reviews” and “Write a Review” then share a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.The liver performs vital functions including filtering toxins, producing proteins, storing energy, aiding digestion, and regulating cholesterol and hormones. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become the most common chronic liver disease globally, affecting up to 38% of the population worldwide.• The liver filters blood, breaks down alcohol and medications, produces proteins like albumin and clotting factors• It stores energy as glycogen, vitamins, and minerals including iron• The liver makes bile for digesting fats and helps regulate cholesterol and support immune function• Common liver problems include fatty liver disease, alcohol use, viral infections, and medication toxicity• MASLD (formerly non-alcoholic fatty liver disease) occurs when too much fat builds up in the liver• MASH is a severe form of MASLD with inflammation and damage that can lead to fibrosis and cirrhosis• Up to 38% of people worldwide have MASLD, with prevalence rising to 65% in those with type 2 diabetes• 5-10% total body weight loss can help slow, stop or reverse liver injury from MASLD• The FDA recently approved semaglutide (Wegovy) as the first specific medication for treating MASH• Regular check-ups with blood tests can help detect liver problems before symptoms developStay healthy, and if you're concerned about your liver health, speak with your healthcare provider about testing and treatment options.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Did you know that nearly one in three people with obesity may have fatty liver disease without even knowing it? In this episode, I talk about groundbreaking news in obesity and liver health, focusing on the FDA's recent approval of WeGovy to treat metabolic dysfunction associated steatohepatitis (MASH) with moderate to advanced fibrosis. I share a personal story about a friend who once struggled with fatigue, abnormal liver tests, and fatty liver disease, highlighting how limited treatment options used to be. I explain what MASH is, why it's so serious, and how common it is, especially among people with obesity and metabolic syndrome.  Furthermore, I dive into the ESSENCE trial, which showed that WeGovy not only improved liver inflammation and scarring but in some cases even reversed the disease, all while emphasizing that it works best when combined with lifestyle changes like healthy eating and regular activity.  Don't miss this episode where I break down the latest breakthrough in liver and weight loss care that could change your health journey!   Episode Highlights: FDA approval of WeGovy for treating MASH with fibrosis The ESSENCE trial results showing improvements in liver health Understanding what MASH is and why it's so common Importance of combining medication with lifestyle changes Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 22, 2025. In this episode: Madrigal regains MASH lead with EU Rezdiffra approval; Viking's obesity data scare investors; China assets lead GLP-1 deals; CSL and others restructure; and Indegene exec on DTP and MFN policies. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T77LV22VANAL5GNPCC2YUVLZBE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

What was meant to simply be a taste test for Brentlyn's Mash it Up Monday suggestion, turned into a whole big mess!

Jesus challenges our understanding of neighborliness through the parable of the Good Samaritan. While religious leaders passed by a wounded man, a Samaritan - someone from a despised group - showed extraordinary compassion. This story redefines 'neighbor' not by cultural, religious, or ethnic boundaries, but by showing mercy to those in need. As disciples of Christ, we must focus less on who qualifies as our neighbor and more on being the best neighbor to anyone God puts in our path. Like a MASH unit positioned near battlefields, we are called to care for all who come our way, regardless of background.

Enjoy the show! You can listen LIVE weekdays 6am-10 Central HERE or on the APP

In this Q&A Mash episode, we answer your burning questions around weight loss resistance, hormone chaos, gut health confusion, and the BS behind one-size-fits-all advice. Liz and Becca dive deep into how context matters more than any single lab result, macro count, or training plan. Inside, we cover: What under-eating really does to your metabolism How overtraining wrecks your hormones Why “normal” labs don't mean jack The #1 mindset shift that moves the needle in healing This episode is your permission slip to stop doing “more” and start doing what's right for your body. *** Get Your Tickets Now: Use code REVIVAL for $100 discount ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠FitMom | UNSTUCK: The Women's Health & Hormone Summit⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ *** Gut & Hormones all messed up? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠➡️ Take the quiz⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ***

22.08.25 Pt 2 Gareth Cliff and Ben Karpinski dive into a wild story about a woman who celebrated beating cancer by hooking up with 200 men — sparking a broader discussion about the secrets and strange origins of Scientology, from alien myths to modern controversies. Mash joins in with a look at the latest lifestyle buzz around “Ozempic butt,” as well as the dangers of self-driving cars that can unexpectedly grind to a halt in the middle of the road. To end things off on a high note, the team celebrates this week's Beautiful Moment: proudly South African words like “gatvol” officially making their way into the Oxford Dictionary. The Real Network

In this episode, our host Maryam Tabatabai is joined by three guests Olivia Pane, PharmD; Dr. Edmundo Rodriguez Frias; and Katie Lockhart, who unpack insights from Prime Therapeutics' latest clinical report that dives into the latest evidence-based clinical insights related to the rising prevalence and significant health impact of metabolic dysfunction-associated steatohepatitis, or MASH. MASH is a silent but serious liver condition affecting over 22 million Americans, with numbers projected to rise sharply by 2030. Listeners learn about the latest major development in liver health treatment: the FDA approval of Novo Nordisk's semaglutide – Wegovy -- as the first GLP-1 drug indicated for MASH. We explore how this development may revolutionize care and could offer a more affordable alternative to treating this condition.The Evolution of GLP-1swww.primetherapeutics.comAll Pharmacy Friends episodesMetabolic dysfunction-associated steatohepatitis (MASH) – A new era in liver healthThe views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice

Great news! If you make a purchase from any link of the links below, the channel earns a small affiliate commission from the site. Many thanks ahead of time. BETTER HELP: https://www.betterhelp.com/JAYREELZ save 10% OFF of your first month. OLIPOP Soda: https://www.drinkolipop.com use promo code JAYREELZ for 15% off of your purchase. BOMBA SOCKS: https://www.gopjn.com/t/2-561785-354075-142593 SAVE 20% CONSUMER CELLULAR: https://www.pntrs.com/t/2-593611-354075-293459 Please subscribe, leave a rating and post a review on Apple Podcasts, Google Podcasts, Spotify, Audacy, Amazon Music and iHeartRadio or wherever you get your podcasts. For daily shorts, weekly vlogs and then some, please subscribe to my YouTube channel at: https://www.youtube.com/channel/UCMucZq-BQrUrpuQzQ-jYF7w If you'd like to contribute to the production of the podcast, please visit my Patreon page at: www.patreon.com/TheJAYREELZPodcast   Many thanks for all of your love and support.   Intro/outro music by Cyklonus. LINKS TO SUBSCRIBE, RATE & REVIEW: APPLE: https://podcasts.apple.com/us/podcast/the-jayreelz-podcast/id1354797894 SPOTIFY: https://open.spotify.com/show/7jtCQwuPOg334jmZ0xiA2D?si=22c9a582ef7a4566 AUDACY: https://www.audacy.com/podcast/the-jayreelz-podcast-d9f50 iHEARTRADIO: https://www.iheart.com/podcast/256-the-jayreelz-podcast-43104270/ AMAZON MUSIC: https://www.amazon.com/The-JAYREELZ-Podcast/dp/B08K58SW24/ref=sr_1_1?dchild=1&keywords=the+jayreelz+podcast&qid=1606319520&sr=8-1

The American Academy of Pediatrics release their own immunization schedule; The American Heart Association update 2017 guidelines for the prevention of high blood pressure; weight loss drug gains indication to treat noncirrhotic MASH; FDA approve a new fibromyalgia treatment; investigational SCD Tx to meet trial endpoint.

Hollywood actor Alan Alda has devoted his life to science, by taking his acting and communication skills off the screen and into the laboratory. Alan grew up in a show business family and spent his childhood touring with a burlesque show run by his parents.He eventually made a name for himself in showbiz, becoming well-known and much-loved for his performances in M.A.S.H. and The West Wing, as well as his roles in many Hollywood films.Alan is also famous for his love of science.He wrote Dear Albert for the stage, based on the love letters of Albert Einstein, which reveal Einstein as a beautifully passionate man.Alan has used his acting for the good of science by teaching communication skills to scientists so they might make their work better known and better understood.Further informationThis interview was first broadcast in December 2016.2025 update:  Alan has been diagnosed with Parkinson's disease, but he says he's managing it well.  Alan is still working occasionally, most recently in the TV remake of his 1981 film ‘The Four Seasons'.You can read all about the Conversations origin story on the ABC News website.This episode of Conversations explores science, science communication, MASH, television, Hollywood, silver screen, acting, show biz families, family business, Vietnam, origin stories, memoir.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

Hollywood actor Alan Alda has devoted his life to science, by taking his acting and communication skills off the screen and into the laboratory.Alan grew up in a show business family and spent his childhood touring with a burlesque show run by his parents.He eventually made a name for himself in showbiz, becoming well-known and much-loved for his performances in M.A.S.H. and The West Wing, as well as his roles in many Hollywood films.Alan is also famous for his love of science.He wrote Dear Albert for the stage, based on the love letters of Albert Einstein, which reveal Einstein as a beautifully passionate man.Alan has used his acting for the good of science by teaching communication skills to scientists so they might make their work better known and better understood.Further informationFirst broadcast December 2016.2025 update:  Alan has been diagnosed with Parkinson's disease, but he says he's managing it well.  Alan is still working occasionally, most recently in the TV remake of his 1981 film ‘The Four Seasons'.You can read all about the Conversations origin story on the ABC News website.This episode of Conversations explores science, science communication, MASH, television, Hollywood, silver screen, acting, show biz families, family business, Vietnam, origin stories, memoir.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

After far too much time away, fair-weather co-host Ash Frith re-joins CheapShow just ahead of its 450th episode and what an episode! It's a nice chunky one that throws Ash in at the deep end straight from the start. They've all got a lot to catch up on and it's been a while since they've all been in the House of Sausage and Mash. It all leads to a 40 minute diversion into the sex, drugs and Rock & Roll private lives of comedians from yesteryear! It's getting censored to F***! After that, it's time for a classic Price of Shite and, to make things more challenging for our returning guest, Eli's confidence and ego is off the charts. There is a mix of tat, toys and musical surprises that must be priced rightly and Paul is struggling to juggle his loyalties! One more episode until 450, it's exciting! See pics/videos for this episode on our website: https://www.thecheapshow.co.uk/ep-449-mumchance SEE US LIVE: Oct 18th @ The Cheerful Earful Podcast Festival 2.30pm, London https://cheerfulearful.podlifeevents.com/festival/cheapshow---live-from-cheerful-earful-podcast-festival-18th-oct-2025-tickets Watch Our 10th Birthday YouTube Live Stream! https://youtube.com/live/Z18i8M3Eqac?feature=share And if you like us, why not support us: www.patreon.com/cheapshow If you want to get involved, email us at thecheapshow@gmail.com For all other information, please visit: www.thecheapshow.co.uk Like, Review, Share, Comment... LOVE US! MERCH Official CheapShow Magazine Shop: www.cheapmag.shop Send Us Stuff: CheapShow PO BOX 1309 Harrow HA1 9QJ

Listener questions? We got 'em. Voicemails? We have those, too! In this episode of MASH Matters, Jeff & Ryan knock a few more questions off the top of the overflowing mailbag. Topics range from MASH vodka dispensers and Cincinnati stalkers to the color of Hawkeye's robe and the size of Klinger's nose. We also, at long last, announce the winner of the MASH fan name poll. All this, plus... Igor is a surgeon?!? Support the podcast on Patreon and buy merch at the MASH Matters store For show notes, episodes, recipes, bios, and more visit our website.  

After far too much time away, fair-weather co-host Ash Frith rejoins CheapShow just ahead of its 450th episode and what an episode! It's a nice chunky one that throws Ash in at the deep end straight from the start. They've all got a lot to catch up on and it's been a while since they've all been in the House of Sausage and Mash. It all leads to a 40 minute diversion into the sex, drugs and Rock & Roll private lives of comedians from yesteryear! It's getting censored to F***! After that, it's time for a classic Price of Shite and, to make things more challenging for our returning guest, Eli's confidence and ego is off the charts. There is a mix of tat, toys and musical surprises that must be priced rightly and Paul is struggling to juggle his loyalties! One more episode until 450, it's exciting! See pics/videos for this episode on our website: https://www.thecheapshow.co.uk/ep-449-mumchance SEE US LIVE: Oct 18th @ The Cheerful Earful Podcast Festival 2.30pm, London https://cheerfulearful.podlifeevents.com/festival/cheapshow---live-from-cheerful-earful-podcast-festival-18th-oct-2025-tickets Watch Our 10th Birthday YouTube Live Stream! https://youtube.com/live/Z18i8M3Eqac?feature=share And if you like us, why not support us: www.patreon.com/cheapshow If you want to get involved, email us at thecheapshow@gmail.com For all other information, please visit: www.thecheapshow.co.uk Like, Review, Share, Comment... LOVE US! MERCH Official CheapShow Magazine Shop: www.cheapmag.shop Send Us Stuff: CheapShow PO BOX 1309 Harrow HA1 9QJ

We are diving back into the fascinating and often frustrating world of direct-to-consumer (DTC) sales. We're thrilled to reconnect with Ari Sussman and welcome Bruce Fougere, co-founder of MASH Networks, a data-driven software company that's truly shaking things up. Ari wastes no time stressing why DTC isn't just an option for distilleries anymore—it's essential. MASH Networks is arming brands with the crucial tools they need to cut through the noise and break those geographic barriers. Bruce then pulls back the curtain on how their tech leverages data and powerful storytelling to turn casual buyers into lifelong fans. We also talk about how all of this has to build on customer loyalty and why consumers are looking meaningful engagement in the brands they support. Show Notes: MASH Networks' impact on craft distilling. The importance of DTC in the evolving market. Effective use of customer data and analytics. Insights from Mammoth Distillery case study. Utilizing QR codes for consumer engagement. Building emotional connections and community. Strategies for tasting experiences and promotions. Exploring subscription models in craft spirits. Support this podcast on Patreon Learn more about your ad choices. Visit megaphone.fm/adchoices

"I was scamming them left and right." Everybody knows that when you stayed home from school you watched Price is Right and rooted for Plinko. Learn more about your ad choices. Visit podcastchoices.com/adchoices